Literature DB >> 25232452

Pancreatic neuroendocrine tumor accompanied with multiple liver metastases.

Tomohide Hori1, Kyoichi Takaori1, Shinji Uemoto1.   

Abstract

Pancreatic neuroendocrine tumor (P-NET) is rare and slow-growing. Current classifications predict its prognosis and postoperative recurrence. Curative resection is ideal, although often difficult, because over 80% of patients have unresectable multiple liver metastases and extrahepatic metastasis. Aggressive surgery for liver metastases is important to improve survival. Aggressive or cytoreductive surgery for liver metastases is indicated to reduce hormone levels and improve symptoms and prognosis. Liver transplantation was originally conceived as an ideal therapy for unresectable liver metastases. Unfortunately, there is no clear consensus on the role and timing of surgery for primary tumor and liver metastases. Surgeons still face questions in deciding the best surgical scenario in patients with P-NET with unresectable liver metastases.

Entities:  

Keywords:  Gastroenteropancreatic neuroendocrine tumor; Liver metastasis; Liver surgery; Liver transplantation; Pancreas

Year:  2014        PMID: 25232452      PMCID: PMC4163742          DOI: 10.4254/wjh.v6.i8.596

Source DB:  PubMed          Journal:  World J Hepatol


  32 in total

1.  ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Authors:  Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

2.  Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?

Authors:  Vincenzo Mazzaferro; Andrea Pulvirenti; Jorgelina Coppa
Journal:  J Hepatol       Date:  2007-07-26       Impact factor: 25.083

Review 3.  Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review.

Authors:  Eliano Bonaccorsi-Riani; Carlos Apestegui; Anne Jouret-Mourin; Christine Sempoux; Pierre Goffette; Olga Ciccarelli; Ivan Borbath; Catherine Hubert; Jean François Gigot; Ziad Hassoun; Jan Lerut
Journal:  Transpl Int       Date:  2010-05-05       Impact factor: 3.782

4.  Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors.

Authors:  Jens Rosenau; Matthias J Bahr; Reinhard von Wasielewski; Michael Mengel; Hartmut H J Schmidt; Björn Nashan; Hauke Lang; Jürgen Klempnauer; Michael P Manns; Klaus H W Boeker
Journal:  Transplantation       Date:  2002-02-15       Impact factor: 4.939

5.  Endocrine tumours of the gastrointestinal tract. Transplantation in the management of metastatic endocrine tumours.

Authors:  Andreas Pascher; Jochen Klupp; Peter Neuhaus
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-08       Impact factor: 3.043

Review 6.  Surgical management of pancreatic neuroendocrine tumors.

Authors:  Wataru Kimura; Koji Tezuka; Ichiro Hirai
Journal:  Surg Today       Date:  2011-09-16       Impact factor: 2.549

7.  Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.

Authors:  Andrea Frilling; Frank Weber; Fuat Saner; Andreas Bockisch; Michael Hofmann; Jan Mueller-Brand; Christoph E Broelsch
Journal:  Surgery       Date:  2006-12       Impact factor: 3.982

8.  Cytoreductive hepatic surgery for neuroendocrine tumors.

Authors:  G P McEntee; D M Nagorney; L K Kvols; C G Moertel; C S Grant
Journal:  Surgery       Date:  1990-12       Impact factor: 3.982

9.  Aggressive surgery for metastatic liver neuroendocrine tumors.

Authors:  Jeffrey A Norton; Robert S Warren; Mary G Kelly; Marlene B Zuraek; Robert T Jensen
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

10.  Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas.

Authors:  R Bettini; W Mantovani; L Boninsegna; S Crippa; P Capelli; C Bassi; A Scarpa; P Pederzoli; M Falconi
Journal:  Dig Liver Dis       Date:  2008-05-07       Impact factor: 4.088

View more
  3 in total

1.  Apatinib inhibits tumor growth and angiogenesis in PNET models.

Authors:  Shan Wu; Jianjun Zhou; Jing Guo; Zhan Hua; Jianchen Li; Zai Wang
Journal:  Endocr Connect       Date:  2019-01-01       Impact factor: 3.335

Review 2.  Heterogeneity of Vascular Endothelial Cells, De Novo Arteriogenesis and Therapeutic Implications in Pancreatic Neuroendocrine Tumors.

Authors:  Bin Ren; J Bart Rose; Yehe Liu; Renata Jaskular-Sztul; Carlo Contreras; Adam Beck; Herbert Chen
Journal:  J Clin Med       Date:  2019-11-14       Impact factor: 4.241

3.  Ectopic spleen and liver hemangioma mimicking metastatic pancreatic neuroendocrine tumor.

Authors:  Christine C Engler; Johannes Lemke; Marko Kornmann; Thomas F Barth; Stefan A Schmidt; Doris Henne-Bruns
Journal:  Int J Surg Case Rep       Date:  2015-11-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.